Phase 2 RCT: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia.

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: #VisualAbstract Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia – Physician’s Weekly

Commentary on Twitter

NEW: Results from the HOVON 139/GiVe, ph 2 trial show that consolidation with venetoclax after fixed-duration venetoclax + obinutuzumab in patients w/ previously untreated CLL increases known side-effects & does not prevent MRD and risk of relapse #lymsm https://t.co/VzCUSHPMrp pic.twitter.com/PB62XNLAIK

— The Lancet Haematology (@TheLancetHaem) March 2, 2022